AIM: Sterol regulatory element-binding protein (SREBP)-1c is the dominant liver insulin-stimulated isoform and strongly correlates with diabetic dyslipidemia characterized by hyperinsulinemia [i.e., high-density lipoprotein cholesterol (HDL-C) levels and hypertriglyceridemia]. MicroRNA (miRNA) 33b is harbored in the intron of SREBP-1c and represses ATP-binding cassette, sub-family A, and member 1 (ABCA1) expression, essential for HDL formation. We measured plasma miRNA33b levels as possible biomarkers for diabetic dyslipidemia in patients with type 2 diabetes mellitus (T2DM) showing insulin resistance. METHODS: The participants included 50 patients with T2DM (M/F 31/19) enrolled in an educational program for controlling blood glucose levels at Hirosaki University Hospital. HbA1c, fasting plasma glucose, insulin, and lipid levels were determined. Plasma miRNA33b, miRNA33a and miRNA148a were quantified using a TaqMan® MicroRNA Assay, and values were corrected with reference to miRNA16. RESULTS: Mean BMI of participants were 28.2±6.6 (kg/m2) and the Homeostasis Model Assessment of Insulin Resistance was 4.3±2.7. Patients' laboratory findings indicated diabetic dyslipidemia with insulin resistance. Plasma miRNA33b/16 levels revealed a positive correlation with plasma insulin level (r=0.326, P=0.021), serum C-peptide (r=0.280, P=0.049), and triglyceride (r=0.351, P=0.012), but no association with HDL-C (r=-0.210, P=0.143). The blood level of miRNA33a was approximately 1/150th of that of miRNA33b and was not correlated with the above parameters. CONCLUSION: We postulated that plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM as well as metabolic syndrome via an insulin/SREBP-1c/miRNA33b/ABCA1 pathway.
AIM: Sterol regulatory element-binding protein (SREBP)-1c is the dominant liver insulin-stimulated isoform and strongly correlates with diabetic dyslipidemia characterized by hyperinsulinemia [i.e., high-density lipoprotein cholesterol (HDL-C) levels and hypertriglyceridemia]. MicroRNA (miRNA) 33b is harbored in the intron of SREBP-1c and represses ATP-binding cassette, sub-family A, and member 1 (ABCA1) expression, essential for HDL formation. We measured plasma miRNA33b levels as possible biomarkers for diabetic dyslipidemia in patients with type 2 diabetes mellitus (T2DM) showing insulin resistance. METHODS: The participants included 50 patients with T2DM (M/F 31/19) enrolled in an educational program for controlling blood glucose levels at Hirosaki University Hospital. HbA1c, fasting plasma glucose, insulin, and lipid levels were determined. Plasma miRNA33b, miRNA33a and miRNA148a were quantified using a TaqMan® MicroRNA Assay, and values were corrected with reference to miRNA16. RESULTS: Mean BMI of participants were 28.2±6.6 (kg/m2) and the Homeostasis Model Assessment of Insulin Resistance was 4.3±2.7. Patients' laboratory findings indicated diabetic dyslipidemia with insulin resistance. Plasma miRNA33b/16 levels revealed a positive correlation with plasma insulin level (r=0.326, P=0.021), serum C-peptide (r=0.280, P=0.049), and triglyceride (r=0.351, P=0.012), but no association with HDL-C (r=-0.210, P=0.143). The blood level of miRNA33a was approximately 1/150th of that of miRNA33b and was not correlated with the above parameters. CONCLUSION: We postulated that plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM as well as metabolic syndrome via an insulin/SREBP-1c/miRNA33b/ABCA1 pathway.
Authors: B Lamarche; K D Uffelman; A Carpentier; J S Cohn; G Steiner; P H Barrett; G F Lewis Journal: J Clin Invest Date: 1999-04 Impact factor: 14.808
Authors: I Shimomura; Y Bashmakov; S Ikemoto; J D Horton; M S Brown; J L Goldstein Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205
Authors: Isabelle Gerin; Laure-Alix Clerbaux; Olivier Haumont; Nicolas Lanthier; Arun K Das; Charles F Burant; Isabelle A Leclercq; Ormond A MacDougald; Guido T Bommer Journal: J Biol Chem Date: 2010-08-22 Impact factor: 5.157
Authors: V Rottiers; S H Najafi-Shoushtari; F Kristo; S Gurumurthy; L Zhong; Y Li; D E Cohen; R E Gerszten; N Bardeesy; R Mostoslavsky; A M Näär Journal: Cold Spring Harb Symp Quant Biol Date: 2011-12-12
Authors: Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando Journal: Science Date: 2010-05-13 Impact factor: 47.728
Authors: Francisco J Ortega; Josep M Mercader; José María Moreno-Navarrete; Oscar Rovira; Ester Guerra; Eduardo Esteve; Gemma Xifra; Cristina Martínez; Wifredo Ricart; Jennifer Rieusset; Sophie Rome; Monika Karczewska-Kupczewska; Marek Straczkowski; José Manuel Fernández-Real Journal: Diabetes Care Date: 2014-01-29 Impact factor: 19.112
Authors: Anne E Justice; Geetha Chittoor; Rahul Gondalia; Phillip E Melton; Elise Lim; Megan L Grove; Eric A Whitsel; Ching-Ti Liu; L Adrienne Cupples; Lindsay Fernandez-Rhodes; Weihua Guan; Jan Bressler; Myriam Fornage; Eric Boerwinkle; Yun Li; Ellen Demerath; Nancy Heard-Costa; Dan Levy; James D Stewart; Andrea Baccarelli; Lifang Hou; Karen Conneely; Trevor A Mori; Lawrence J Beilin; Rae-Chi Huang; Penny Gordon-Larsen; Annie Green Howard; Kari E North Journal: Epigenomics Date: 2020-09-09 Impact factor: 4.778
Authors: Perrine Goguet-Rubio; Rebecca L Klug; Dana L Sharma; Krithika Srikanthan; Nitin Puri; Vishal H Lakhani; Alexandra Nichols; Kathleen M O'Hanlon; Nader G Abraham; Joseph I Shapiro; Komal Sodhi Journal: Int J Med Sci Date: 2017-04-19 Impact factor: 3.738